Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Emmanuel Mignot
Person

Emmanuel Mignot

Tracked across 2 events · 27 articles · First seen Jun 15, 2026 · Last active Aug 19, 2026

Sentiment
50
Attention
6
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
6 50
Tech
Takeda Oveporexton Improves Narcolepsy Symptoms
Impact: Emmanuel Mignot is the principal investigator for the FirstLight Phase 3 study, providing expert commentary on the significance of oveporexton's results for narcolepsy type 1 patients.
Jun 15, 2026 · 6 articles
6 50
Regulatory
FDA Approves Takeda's Orzeyful for Narcolepsy Type 1
The U.S. United States — Food and Drug Administration (FDA) approved Takeda Pharmaceutical Company's Orzeyful (oveporexton) as the first oral orexin receptor 2 agonist for the treatment of narcolepsy type 1 (NT1) in adults. This…
Impact: As principal U.S. investigator in the Phase III program, Emmanuel Mignot highlighted the drug's ability to treat the broad spectrum of NT1, enabling a different conversation about treatment options.
Aug 05, 2026 · 21 articles
ERGEN INTELLIGENCE
Track Emmanuel Mignot live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.